Changes to This Summary (02/28/2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Updated statistics with estimated new cases and deaths for 2014 (cited American Cancer Society as reference 1).
Added text to state that the natural histories of these tumors are variable, depending on histological and molecular factors; therefore, treatment guidelines are evolving. Also revised text to state that therapy involving surgically implanted carmustine-impregnated polymer wafers combined with postoperative external-beam radiation therapy may play a role in the treatment of high-grade gliomas (grade III and IV gliomas) in some patients.
Revised the Glioblastomas subsection extensively.
Revised text to state that patients who have oligodendrogliomas (WHO grade II) generally have a better prognoses than do patients who have diffuse astrocytomas; however, most of the oligodendrogliomas eventually progress.
Added text to include stereotactic radiosurgery for tumors less than 3 cm as a standard treatment option for grade 1 meningiomas and revised a treatment option to read fractionated radiation therapy for patients with resectable tumors.
Added Bevacizumab as a new subsection.
Revised text to add lomustine as an additional systemic chemotherapy drug.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.